Skip to main content

What the FDA labels say about taking them together

Erythromycin and nintedanib

Nintedanib's FDA label of November 20, 2025 names erythromycin in its drug interactions section; the erythromycin labels PlainMeds reads (4) do not name nintedanib. The nintedanib label: “Concomitant use of P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib.”

Check it at the source: the erythromycin FDA label on DailyMed (effective August 1, 2024, Teva Pharmaceuticals USA, Inc.); the nintedanib FDA label on DailyMed (effective November 20, 2025, Boehringer Ingelheim Pharmaceuticals, Inc.).

What does the erythromycin label say about nintedanib?

Erythromycin's label (effective August 1, 2024) and its 3 other brand-application labels do not name nintedanib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Erythromycin), Teva Pharmaceuticals USA, Inc., effective August 1, 2024 (SPL set 75a0bd5a-d09f-483b-bfd8-f8343b149eb2), via openFDA; the full label on DailyMed

What does the nintedanib label say about erythromycin?

Nintedanib label, drug interactions

Concomitant use of P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib [see Clinical Pharmacology (12.3) ].

Source: FDA drug label (Ofev), Boehringer Ingelheim Pharmaceuticals, Inc., effective November 20, 2025 (SPL set da1c9f37-779e-4682-816f-93d0faa4cfc9), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

38Erythromycin generic labelers
11Nintedanib generic labelers
ErythromycinNintedanib
Labeled forBacterial infections, Acnen/a
Boxed warningNoNo
Pharmacy cost (NADAC)$1.96 per tablet 250 mg tablet$13.46 per capsule 150 mg capsule
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?